For citations:
Mareev V.Yu., Orlova Y.A., Plisuk A.G., Pavlikova E.P., Akopyan Z.A., Matskeplishvili S.T., Malahov P.S., Krasnova T.N., Seredenina E.M., Potapenko A.V., Agapov М.A., Asratyan D.A., Dyachuk L.I., Samokhodskaya L.M., Mershina E.M., Sinitsyn V.E., Mareev Yu.V., Shatokhina E.A., Begrambekova Yu.L., Kamalov A.A. Proactive anti-inflammatory therapy in the advanced stages of a new coronavirus infection. Main results of the inpatient phase of the COLORIT study (Colchicin vs. Ruxolitinib and secukinumab in an open, prospective, randomized trial in patients with novel coronavirus infection COVID-19). Kardiologiia. 2022;62(12):11-22. https://doi.org/10.18087/cardio.2022.12.n2316
Email this article 
Post a Comment 
